Clinical Compendium: Advancing the Care of Patients With Type 2 Diabetes and Chronic Kidney Disease: Role of the Glucagon-like Peptide-1 Receptor Agonists
Released On
February 6, 2023
Expires On
February 6, 2024
Media Type
Internet
Completion Time
90 minutes
Specialty
Cardiology, Endocrinology, Nephrology, Other, Primary Care
Topic(s)
Cardiovascular Disease, Diabetes
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Annenberg Center for Health Sciences at Eisenhower.
Supported by an educational grant from Novo Nordisk Inc.
Credit Available
- 1.50 ACPE Contact Hours
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 ANCC Contact Hours
- 1.50 CA-BRN Contact Hours
- 1.00 Pharmacology Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity was developed for nephrologists, endocrinologists, family physicians, physician assistants, nurse practitioners, pharmacists and other clinicians interested in the prevention and management of nephropathy in patients with type 2 diabetes.
Program Overview
Nephrologist and clinical trialist George Bakris, MD, reviews the burden of diabetic kidney disease (DKD) and provides guideline recommendations to properly screen and prevent cardiovascular disease events in patients with DKD. Fellow clinical trialist and diabetes expert John Buse, MD, PhD, discusses the pharmacology and prescribing considerations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and highlights this class while reviewing new consensus reports. Dr. Buse teams up with Dr. Bakris to discuss the cardiorenal benefits of GLP-1 RAs evidenced by cardiovascular outcomes trials and recent meta-analyses. Primary care and internal medicine specialist John Anderson, MD, joins Drs. Bakris and Buse to lead the discussion of 2 cases of patients with DKD. Dr. Anderson concludes by discussing the importance of multidisciplinary management in optimizing care for our patients with type 2 diabetes and chronic kidney disease.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the impact of diabetes on the progression of chronic kidney disease and cardiovascular disease.
- Differentiate glycemic and nonglycemic effects among glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
- Describe the efficacy, safety, and role of GLP-1 RAs in the treatment of adults with type 2 diabetes, chronic kidney disease, and established atherosclerotic cardiovascular disease.
- Initiate evidence-based GLP-1 RA therapy in patients with T2D and CKD.
Faculty
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
George Bakris, MD
Professor of Medicine
Director, American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois
John B. Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Senior Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Joint Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.50 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Nursing Continuing Education Credit Designation
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.50 contact hours, including 1.00 pharmacology hour.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.50 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Disclosures of Conflicts of Interest
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relationships with ACCME-defined ineligible companies.
The Annenberg Center for Health Sciences assesses relevant relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant relationships that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
- John E. Anderson, MD
- Consultant: Abbott Diabetes, AlfaSigma, AstraZeneca, Bayer, Boerhinger Ingelheim, Eli Lilly, Intuity Medical, Novo Nordisk, Sanofi
- Speaker: AstraZeneca, Bayer, Eli Lilly, Novo Nordisk, Sanofi
- George Bakris, MD
- Consultant: Alnylam, AstraZeneca, Bayer, DiaMedica Therapeutics, inRegen, Ionis, KBP Biosciences, Novo Nordisk
- Steering Committee: Alnylam, AstraZeneca, Bayer, DiaMedica Therapeutics, inRegen, Ionis, KBP Biosciences, Novo Nordisk
- John B. Buse, MD, PhD
- Consultant: Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, CeQur, Cirius Therapeutics, Eli Lilly, GentiBio, Glycadia, Glyscend, Janssen, MannKind, Mellitus Health, Moderna, Pendulum Therapeutics, Praetego, Sanofi, Stability Health, Terns, Valo, Zealand Pharma
- Stock/Stock Options: Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, Stability Health
The faculty for this enduring activity has disclosed that there will be discussion about the use of products for non-FDA approved applications.
Additional content planners:
Eugene Cullen, MD (Peer Reviewer), has no significant relationship to disclose.
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Reviewer), has no significant relationship to disclose.
Chandler David Schexnayder, PharmD, BCPS, CDCES, BCACP (Medical Writer), has no significant relationship to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications in your practice, and completing the assessment component.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information
For CME questions please contact:
[email protected]